SCHEDULE 13D/A: Cartesian Therapeutics Director Timothy Springer Significantly Increases Stake to 36.9%

Timothy A. Springer, a director of Cartesian Therapeutics, Inc., has substantially increased his beneficial ownership in the company to 36.9% through recent open market purchases and equity grants.

Summary

• Dr. Timothy A. Springer, a director of Cartesian Therapeutics, Inc., now beneficially owns 9,555,394 shares, representing approximately 36.9% of the company's outstanding common stock as of January 15, 2025.
• This ownership includes shares held directly, shares underlying warrants and options exercisable within 60 days, and shares held by TAS Partners LLC and Dr. Chafen Lu (Dr. Springer's spouse).
• On January 13, 2025, Dr. Springer acquired 16,945 shares in open market purchases at prices ranging from $16.40 to $18.00 per share, totaling approximately $293,957.
• On January 14, 2025, Dr. Springer further acquired 4,022 shares in open market purchases at $18.00 per share, totaling approximately $72,396.
• These open market acquisitions were funded using Dr. Springer's personal funds.
• Additionally, on January 2, 2025, Dr. Springer was granted 2,600 restricted stock units and options to purchase 7,800 shares at an exercise price of $16.93 per share, both vesting in full on January 2, 2026, for his service on the board of directors.
• TAS Partners LLC beneficially owns 563,206 shares (2.2%), and Dr. Chafen Lu beneficially owns 350,740 shares (1.4%).
• The percentages of beneficial ownership are based on 25,725,306 shares issued and outstanding as of November 22, 2024.

Sentiment

Score: 9

Explanation: The sentiment is highly positive due to the significant increase in beneficial ownership by a key director, Timothy A. Springer, through substantial open market purchases and equity grants. This indicates strong insider confidence and alignment with shareholder interests.

Positives

• Significant increase in insider ownership by a key director, Timothy A. Springer, signaling strong confidence in the company's future.
• Dr. Springer's substantial personal investment of approximately $366,353 in open market purchases demonstrates a direct financial commitment.
• The equity grants (RSUs and options) align Dr. Springer's interests with long-term shareholder value.

Future Outlook

The document does not contain explicit forward-looking statements or guidance regarding the company's future performance or strategic direction, beyond the vesting schedule of equity grants.

Industry Context

This filing primarily concerns changes in beneficial ownership by a key insider and does not provide broader industry context or trends. However, significant insider buying in a biotechnology company can be interpreted as a positive signal regarding the company's pipeline or strategic direction within the competitive biotech landscape.

Related Party Transactions

• On January 2, 2025, Dr. Springer was granted 2,600 restricted stock units and options to purchase 7,800 shares for his service on the board of directors.
• Dr. Chafen Lu, who beneficially owns 350,740 shares, is the spouse of Dr. Timothy A. Springer.

Stakeholder Impact

• Shareholders may view the increased insider ownership as a positive indicator of management's confidence in the company's future, potentially leading to increased investor confidence and share price stability.
• The equity grants to Dr. Springer align his financial interests more closely with the long-term performance of the company, benefiting all shareholders.

Next Steps

• Restricted stock units and options granted to Dr. Springer are scheduled to vest in full on January 2, 2026.

Key Dates

Recommendation

Keywords

Cartesian Therapeutics, Timothy A. Springer, TAS Partners LLC, Chafen Lu, Beneficial Ownership, Insider Buying, SEC Schedule 13D, Common Stock, Equity Stake, Restricted Stock Units, Stock Options, Biotechnology, Pharmaceuticals